ArticleEClinicalMedicine2026

Dapiglutide, a dual GLP-1 and GLP-2 receptor agonist, for obesity: a randomised, double-blind, placebo-controlled parallel-group, proof-of-concept trial.

Casper K Nielsen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.